EPM chats with Pratima Cherukuri, chief scientific officer, Genezen, who shares the considerations in the development and manufacture of lentiviral vectors, and highlights some of the challenges organisations may face as they look to bring these potentially life saving therapies to market.
Key insights:
- Lentiviruses' advancement in C>s can be seen in the success of CAR-T therapies, representing 48% of all technology in the genetically modified cell therapy development pipeline.
- One of the most prevalent challenges that developers and manufacturers are facing in lentivirus production currently is the desire for stable producer cell lines.
- LV developers can adapt adherent cell lines to suspension systems, which are associated with ease of scaling and high levels of control over culture parameters.
Q. As a tool for introducing genetic material to patient cells in cell and gene therapy (C>) applications, what key considerations need to be made when selecting a viral vector?